

Edgar Filing: Abraxis BioScience, Inc. - Form 425

Abraxis BioScience, Inc.  
Form 425  
July 08, 2010

Filed by Celgene Corporation  
Pursuant to Rule 425 of the Securities Act of 1933  
and deemed filed pursuant to Rule 14a-12  
of the Securities Exchange Act of 1934  
Subject Company: Abraxis BioScience, Inc.  
Commission File No.: 001-33657

The following document represents an excerpt from an internal publication of Celgene Corporate Communications that was distributed to employees of Celgene Corporation, or Celgene, related to the announcement by Celgene of its proposed acquisition of Abraxis BioScience, Inc..

---

**Hppnp Tuesday July 6, 2010 The Morning Notes A New Chapter Set to Begin for Celgene** *Abraxis Acquisition is an Exceptional Strategic Fit Expanded pipeline, targeted therapeutics and solid-tumor therapies, create expansive opportunities* A major milestone was realized last week when **Bob Hugin**, Celgene CEO, announced that Celgene had signed an agreement to acquire Abraxis Bio-Science, a California-based biotechnology company headquartered in Los Angeles. For the team members throughout Celgene, news of this major transaction has created a greater level of enthusiasm, evident by the reactions in Celgene offices worldwide. Along with this, and following the closing of the acquisition and integration of Abraxis technologies and products, we will be afforded new opportunities to help even more patients through an expanded portfolio of treatment options. Of particular note will be our ability to immediately address for the first time the solid-tumor segment of the oncology market. Through leveraging our existing capabilities and expertise in hematology and oncology we can help advance commercialization efforts to provide patients these much needed therapies. Through this acquisition, we are advancing our global strategy and making important strides toward critical work in the field of oncology, becoming a world leader in the discovery and development of novel approaches to rare and debilitating diseases. **About Abraxis... Values, Mission, Complement and Support Celgene Strategic Plan** Sharing a similar philosophy and commitment of improving the lives of patients around the world helps make the Abraxis BioScience acquisition an ideal fit. Through this new synergy and in alignment with our goals and mission we will be afforded a greater opportunity to alter the course of diseases through the use of cutting-edge, next-generation therapies. By combining resources and technologies, a unified Celgene can further advance its efforts to shift the paradigm of treatment for patients, offering new therapeutic options, targeted on an expanded product portfolio. In addition to its headquarters location in Los Angeles, California, Abraxis BioScience also has other locations in the United States, Canada and China. U.S. locations include: Phoenix, Arizona; Chicago, Illinois; Durham, North Carolina, and Bridgewater, New Jersey. Richmond Hill, Ontario, is the location of the Canadian office. And, the Switzerland location is in Barbengo; and, Beijing is home to the location in China. The Abraxis product pipeline includes more than five clinical oncology product candidates in various stages of testing and development. At the center of its solid-tumor focus is Abraxan®, a therapeutic compound launched in 2005, and based on its proprietary tumor targeted technology, nab technology platform. Abraxane currently is marketed in the United States for the treatment of metastatic breast cancer. *(continued to page 4)*

---

**Abraxis BioScience (Abraxane\* Page 2 Toesday.Jnly6.2010 The Morning NoteS** (continued from page 1) § *Current Abraxis Locations* Richmond Hill, London, UK  
0 nte rio. Ca nada Barbengo, los Anaelw, CA Cdgene Abraxis BioScience Pipeline Regulatory Filing & Preclinical \_\_\_\_\_ PHASE I PHASE II PHASE III \_\_\_\_\_ Approval ABRAXANE® Breast (Metastatic) Lung (Advanced) Metastatic Melanoma Pancreatic (Advanced) ABI-008(na0®-docetaxel) Prostate (Hormone Refractory) ABI-009 (nitf^-rapamycin) mTOR Inhibitor-Solid Tumors ABI-011(1)31^-5 404) Vascular Disrupting Agent -Solid Tumors ABI-013(nail^-CY196) ABI-010 (ns^-17AAG) HspSO Inhibitor-Solid Tumors **Current Abraxis product Pipeline** (continued on page 5) *The Morning Notes is a publication of Celgene Corporate Communications; it is confidential and for internal use only by Celgene Employees.*

---

Page 3 **Tuesday, July 6, 2010 The Morning Notes (continued from page 4)** V Abraxis Albumin shell - Paclitaxel **Abraxis** (continued on page 6) *The Morning Notes* is a publication of Celgene Corporate Communications; it is confidential and for internal use only by Celgene Employees.

---

**Page 4 Tuesday, July 6, 2010 The Morning Notes (continued from page 5)** fCdgene Emerging Solid Tumor Pipeline: 2015 Regulatory Filing & Preclinical \_\_\_\_\_ PHASE I \_\_\_\_\_ PHASE II \_\_\_\_\_ PHASE III \_\_\_\_\_ Approval ABRAXANE \_\_\_\_\_ Breast (Metastatic) Lung (Advanced) Malignant Melanoma Pancreatic (Advanced) AMRUBICIN \_\_\_\_\_ SCLC b; REVLIMID® Solid Tumors Prostate Cancer Colorectal Cancer Renal Cell Carcinoma ACE-011 CIA in Breast Cancer ABI-009 (naib^rapamycin) mTOR Inhibitor-Solid Tumors ABI-011(na^94D4) Vasular Disrupting Agent -Solid Tumors ABI-013(natScY196) ABM10(natfM7AAG) Hsp90 Inhibitor-Solid Tumors (rdeene Significant Potential: 2015 & Beyond *Celgene Expanding Pipeline -Abraxane\** Hematoiology Reylimid Hematology, l&lbi-axane *Apremilas Pomalidomide* /isifioAX **Abraxane Pomalidomide** Hematology \_\_\_\_\_ Hematology *Apremilast hthalomd* Amrubicin Hsmatology ACE-011 **THALOMID** JNKCC-930 Amrubicin \_\_\_\_\_ PDA-001 Amrubicin Amrubicin \_\_\_\_\_ PDA-001 GI4000 **2010 2015 2020** (continued on page 7) *The Morning Notes is a publication of Celgene Corporate Communications; it is confidential and for internal use only by Celgene Employees.*

---

Pages **Tuesday, July 6, 2010** the **Morning Notes** (continued from page 6) **About the Acquisition ... Wall Street Responds Positively to New Deal** Market Nods on Good News celger **Company Update** \_\_\_\_\_  
**BUY Equity** United States 3ia:irHlagy 10 July 2010 celg buys abll- good fit **Banahof America Merrill Lynch** Rachel McMiwi +1 4156763575 (9 **Rew9rch\*fi,Jy5t ML^FSS** HcheLiriEmhiifiliarl.cDni Masha Chapman +14156763575 **FtaeadiAn^Et ABII deal fits with CELG s strategic goals** CELG yesterday announced plans to acquire ABII, primarily for Abraxaric which is a chemotherapy approved for metastatic breast cancer with 2009 sales of \$315M. The deal fits with CELG's goal of delivering 25% bottom line growth over the next J.P. Morgan Celgene  
Celgene to Acquire Abraxis: Accelerates Expansion into Solid Tumors- **ALERT** Chj inrtfliini, Cd^rtc Jlrfi.4Jlh.ihJ ll li\*> .nl iii A ,-iiiiMi . IN.I...-I MftMfmiiiiih rx ^piiuuH **Id**. Celgene (nasdaq: celg; 53.2-4)  
Abraxis Acquisition Makes Strategic Sense; Good Entry into Solid Tumors **Outperform** Celgene  
Cooperation Positive on the Abraxis Acquisition; Entry Into Solid-Tumor Market for a Reasonable Price  
Biotechnology Research June 30, 2010 Celgene Corporation (CELG) oHEM (CELG) We Like Abraxis  
Deal Company 30 June 2010 | 8 page Celgene Corp (CELG) Abraxis Deal is Solid Step to Building  
Long-Term Value **The Morning Notes is a publication of Celgene Corporate Communications; it is confidential and for internal use only by Celgene Employees.**